Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Other Operating Expenses (2020 - 2024)

Climb Bio filings provide 5 years of Other Operating Expenses readings, the most recent being $51.7 million for Q2 2024.

  • Quarterly Other Operating Expenses changed N/A to $51.7 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $51.7 million through Mar 2025, changed N/A year-over-year, with the annual reading at $51.7 million for FY2024, N/A changed from the prior year.
  • Other Operating Expenses hit $51.7 million in Q2 2024 for Climb Bio, up from $900000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $51.7 million in Q2 2024 and bottomed at $20000.0 in Q3 2021.
  • Average Other Operating Expenses over 5 years is $7.8 million, with a median of $200000.0 recorded in 2021.
  • The largest annual shift saw Other Operating Expenses plummeted 99.36% in 2021 before it surged 958.82% in 2023.
  • Climb Bio's Other Operating Expenses stood at $9.4 million in 2020, then plummeted by 99.36% to $60000.0 in 2021, then soared by 41.67% to $85000.0 in 2022, then surged by 958.82% to $900000.0 in 2023, then surged by 5639.89% to $51.7 million in 2024.
  • Per Business Quant, the three most recent readings for CLYM's Other Operating Expenses are $51.7 million (Q2 2024), $900000.0 (Q1 2023), and $85000.0 (Q1 2022).